The Relationship Between Hypertension and Inflammation (R01)
Posted by National Institutes of Health
Opportunity snapshot. This Grants.gov announcement — The Relationship Between Hypertension and Inflammation (R01) — is cataloged under number PA-07-138 and tied to CFDA assistance listing 93.837, posted by National Institutes of Health. Grants.gov currently shows the opportunity as open, first posted on December 12, 2006 and last updated on December 5, 2008. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity is open, but Grants.gov has not published a hard closing date — check the official listing for the current deadline and any posted amendments. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully — federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed — it helps clarify scope and scoring priorities.
Award Range
Varies by applicant
Close Date
Not specified
Multiple Receipt Dates - See Link to Full Announcement for details.
Posted
December 12, 2006
Instrument
Grant
Description
-Purpose. This Funding Opportunity Announcement (FOA) solicits grant applications that propose the study of the sequence of events in which the vascular inflammatory state contributes to the development and maintenance of hypertension. Ample evidence suggests that inflammation may play a role in the pathogenesis of hypertension or that it may characterize a functional state of the vessel wall as a consequence of high blood pressure. Angiotensin II (Ang II), a widely recognized vasoconstrictor and anti-natriuretic involved in blood pressure regulation, also acts as a pro-inflammatory factor in the cardiovascular system. Ang II stimulates the expression of several inflammatory cytokines, which in turn affect blood pressure. A potential linkage between Ang II and immuno-cytokines is their shared ability to induce the level of reactive oxygen species (ROS), which serve as second messengers for many intracellular signaling pathways. The production of ROS not only decreases bioavailability of nitric oxide (NO), a vasodilator, but also initiates the functional and morphological alterations, such as remodeling, in the vascular wall that accompany the hypertensive state over time. This FOA would provide an opportunity to bring focus on the potential causal relationship between hypertension and inflammation in a cohesive, integrated manner. A new understanding of hypertension and inflammation would provide novel opportunities to prevent and treat the disease. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the numbers, quality, duration, and costs of the applications received.
Eligibility
00;01;02;04;05;06;07;08;11;12;13;20;22;23;25
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Heart and Vascular Disease Research
National Institutes of Health
Agency Contact
NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology — how this data is sourced, computed, and verified.
Related
| Publisher | Kiznis Studio |
| Sources | Public official public datasets |